[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-rhinosinusitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-rhinosinusitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,42,70,97,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100619114","phase-2-effect-of-chinese-herbal-medicine-nasal-irrigation-on-the-postoperative-care-of-chronic-rhinosinusitis-100619114",false,"NCT07340411","Effect of Chinese Herbal Medicine Nasal Irrigation on the Postoperative Care of Chronic Rhinosinusitis","Breeze Clear","Inclusion Criteria:\n\n* 1\\. Patients with chronic rhinosinusitis who failed medical treatment 2.Patients underwent bilateral primary functional endoscopic sinus surgery.\n\nExclusion Criteria:\n\n* 1\\. Patients with a history of immunodeficiency 2.Patients with a history of sinus surgery 3.Patients who receiving antibiotic treatment within a week before functional endoscopic sinus surgery 4.Patients with a pathological diagnosis of fungal sinusitis 5.Patients with a pathological diagnosis of sinonasal tumor","ALL","18 Years","90 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Investigators tried to evaluate the efficacy and safety of Chinese herbal medicine nasal irrigation as an adjuvant therapy after FESS.",[27,28],"Chronic Rhinosinusitis","Postoperative Care","RECRUITING","2026-01-05",{"date":32,"type":33},"2026-01-14","ACTUAL",{"date":35,"type":33},"2023-07-05",{"date":37,"type":21},"2026-03-31",{"name":39,"class":40},"Taichung Veterans General Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100613723","phase-1-nebulized-nasal-steroids-100613723","NCT07270302","Nebulized Nasal Steroids","Safety and Efficacy of Nebulized Nasal Steroids for the Treatment of Chronic Rhinosinusitis","Inclusion Criteria:\n\n* Age 18 or older that meet diagnostic criteria for CRS with or without polyposis as documented by their recruiting physician.\n* Diagnostic criteria for CRS will be defined according to EPOS criteria of \\>12 weeks of 2 of the following subjective symptoms: nasal blockage or obstruction, rhinorrhea, hyposmia, or facial pain\u002Fpressure AND objective evidence of CRS on either nasal endoscopy or CT scan\n\nExclusion Criteria:\n\n* Patients who have previously undergone sinus surgery\n* Severe polyposis; defined as Lund Kennedy endoscopy score greater than 1\n* Patients who are currently using or who have previously used biologic medications for their nasal polyps. These medications include: dupilumab, omalizumab, mepolizumab, tezepelumab, or depemokimab\n* Inability to complete surveys in English\n* known comorbid mucociliary disease\n* known adrenal disease or other HPA dysfunction\n* patients taking oral corticosteroids for other medical conditions\n* oral antibiotic administration within 2 weeks of study participation\n* a baseline SNOT-22 score less than 9, due to inability to achieve the MCID",{"count":50,"type":21},50,[52,24],"PHASE1","The goal of the proposed project is to assess the efficacy, safety, and patient experience of budesonide administered via the NasoNeb system for medical management of CRS. The authors propose a randomized controlled trial of nebulized budesonide via the NasoNeb compared against budesonide lavage.",[27],[56,57,58,59],"Otolaryngology","Pharmacology","Pharmacy","intranasal steroid sprays","NOT_YET_RECRUITING","2025-11-26",{"date":63,"type":33},"2025-12-08",{"date":65,"type":21},"2025-12",{"date":67,"type":21},"2026-05",{"name":69,"class":40},"Washington University School of Medicine",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100597791","efficacy-of-erythromycin-phonophoresis-on-chronic-rhinosinusitis-100597791","NCT07063082","Efficacy Of Erythromycin Phonophoresis on Chronic Rhinosinusitis","Inclusion Criteria:\n\n* Age range between 25-50 years.\n* Male and female patients will participate in the study.\n* All patients have chronic rhinosinusitis.\n* All patients enrolled in the study will have their informed consent.\n* CT will include at least affection of maxillary sinus.\n\nExclusion Criteria:\n\n* Patients with pacemaker\n* Patients diagnosed with cancer.\n* Pregnant women\n* Patients with impaired vascular circulation\n* Patients who suffer from mental or psychological disorders.\n* Patients with any systemic diseases that may interfere with the objectives of the study.\n* Congenital defects on face and nose.\n* Fracture of nose or face.\n* Polypoidal patients.\n* Allergic patients.\n* Previous nasal surgery.","25 Years","50 Years",{"count":79,"type":21},90,[81],"NA","The purpose of the study is to evaluate the therapeutic effect of erythromycin phonophoresis in reducing chronic rhinosinusitis.",[27],[85,86,87],"Erythromycin","Phonophoresis","ultrasound","2025-07-02",{"date":90,"type":33},"2025-07-14",{"date":92,"type":21},"2025-07-07",{"date":94,"type":21},"2025-09-15",{"name":96,"class":40},"Cairo University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":41},"100580419","the-effect-of-modified-olfactory-training-on-postoperative-olfactory-dysfunction-in-patients-with-crs-100580419","NCT06837051","The Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With CRS","Protocol for a Randomized Controlled Trial Evaluating the Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With Chronic Rhinosinusitis","Inclusion Criteria:\n\n1. A diagnosis of CRSsNP based on the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS20).\n2. The duration after endoscopic sinus surgery is 3months.\n3. Olfactory dysfunction confirmed with the Sniffin's Sticks psychophysical test (TDI score≦30.5) .\n4. Willingness to participate in this study and sign the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Patients with olfactory impairment due to traumatic, congenital, toxic\u002Fdrug-induced causes, tumors, or post-upper respiratory infections.\n2. Lund-Mackay olfactory cleft score \\> 0.\n3. Patients with severe comorbidities, such as malignant tumors.\n4. Current or planned pregnancy prior to the end of study.\n5. Patients who are unable to complete the study or are unable to comply with the requirements of the study (such as inability to tolerate olfactory function testing and treatment, memory or behavioral abnormalities, depression, smoking, heavy alcohol use, previous delinquent behavior)","80 Years",{"count":106,"type":21},213,[81],"The goal of this clinical trial is to validate the effectiveness of the modified olfactory training device, the main questions it aims to answer are:\n\nIs it possible that the device can treat postoperative olfactory dysfunction in patients with chronic sinusitis? Compared to the conventional device, how efficient is the modified olfactory training device for treating postoperative olfactory dysfunction in patients with chronic sinusitis?",[110,27],"Olfactory Dysfunction",[112,113,114,115],"olfactory dysfunction","chronic rhinosinusitis","endoscopic sinus surgery","olfactory training","2025-02-14",{"date":118,"type":33},"2025-02-20",{"date":120,"type":21},"2025-03-14",{"date":122,"type":21},"2027-03-14",{"name":124,"class":40},"Peking University Third Hospital",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":135,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":41},"100511149","rhinosinusitis-italian-network-the-italian-registry-for-severe-uncontrolled-chronic-rhinosinusitis-100511149","NCT05935683","Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis","Rhinosinusitis Italian Network (RINET): the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis","RINET","Inclusion Criteria:\n\n* Participants with a confirmed diagnosis of bilateral Chronic Rhinosinusitis that have at least three (in case of patients previously treated with surgical approaches) or four (in case of patients never treated with nasal sinus surgery) of the following criteria:\n\n  * Evidence of type 2 inflammation (at least 250 blood eosinophils per microliter and \u002F or at least 10 eosinophils \u002F HPF from a histological sample of sinus mucosa and \u002F or at least one finding of moderate eosinophilia on nasal cytology and \u002F or total serum IgE \\>100 IU \u002F ml);\n  * at least two Short courses of systemic corticosteroids or lorg-term Systemic Corticosteroids therapy for Chronic Rhinosinusitis;\n  * Significant deterioration in the quality of life (Sinonasal Outcome Test 22 - SNOT-22\\>= 40 and \u002F or Visual Analogue Scale - Global VAS of symptoms\\>= 5);\n  * Loss of Smell (VAS for hyposmia\\> = 7)\n\nExclusion Criteria:\n\n\\-",{"count":134,"type":21},5000,"10 Years","OBSERVATIONAL","This observatory aims to collect, as widely as possible, the Italian cases of patients with uncontrolled CRS. Patient will be enrolled by the centers of the Italian Network of Rhinosinusitis (Rhinosinusitis Italian Network: RINET), and they will be treated using a multidisciplinary team approach (allergists, otolaryngologists and pneumologists) in a real-world clinical set-up.\n\nThis real-life chronic rhinosinusitis registry aims at longitudinal data collection from patients attending specialist care centres across Italy.",[27],[140,141,142,143,144,145,146,147],"chronic rhinosinusitis with nasal polyps","chronic rhinosinusitis without nasal polyps","Otorhinolaryngologic Diseases","Respiratory Tract Diseases","Paranasal Sinus Diseases","Sinusitis","Nose Diseases","chronic rhinosinusitis (diagnosis)","2024-07-18",{"date":150,"type":33},"2024-07-19",{"date":152,"type":33},"2021-11-01",{"date":154,"type":21},"2031-10-31",{"name":156,"class":40},"Italian Academy of Rhinology"]